120 related articles for article (PubMed ID: 23237222)
1. The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China.
Zhou QM; Li W; Guan YX; Zhang X; Chen XC; Ding Y; Wen XZ; Peng RQ; Yan SM; Zhang XS
Chin J Cancer; 2013 Jul; 32(7):410-4. PubMed ID: 23237222
[TBL] [Abstract][Full Text] [Related]
2. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C; Killian KJ; Samuels Y; Rudloff U
Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
[TBL] [Abstract][Full Text] [Related]
3. Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.
Mirkina I; Hadzijusufovic E; Krepler C; Mikula M; Mechtcheriakova D; Strommer S; Stella A; Jensen-Jarolim E; Höller C; Wacheck V; Pehamberger H; Valent P
PLoS One; 2014; 9(1):e84417. PubMed ID: 24489649
[TBL] [Abstract][Full Text] [Related]
4. A growing family: adding mutated Erbb4 as a novel cancer target.
Rudloff U; Samuels Y
Cell Cycle; 2010 Apr; 9(8):1487-503. PubMed ID: 20404484
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Prickett TD; Agrawal NS; Wei X; Yates KE; Lin JC; Wunderlich JR; Cronin JC; Cruz P; Rosenberg SA; Samuels Y
Nat Genet; 2009 Oct; 41(10):1127-32. PubMed ID: 19718025
[TBL] [Abstract][Full Text] [Related]
6. Aberrations and clinical significance of BRAF in malignant melanoma: A series of 60 cases in Chinese Uyghur.
Kang X; Zeng Y; Liang J; Li J; Ren D; Chai L; Sun Z; Yu S; Wu X; Han W; Wang W
Medicine (Baltimore); 2018 Jan; 97(1):e9509. PubMed ID: 29505523
[TBL] [Abstract][Full Text] [Related]
7. High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.
Daniels AB; Lee JE; MacConaill LE; Palescandolo E; Van Hummelen P; Adams SM; DeAngelis MM; Hahn WC; Gragoudas ES; Harbour JW; Garraway LA; Kim IK
Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):6991-6. PubMed ID: 22977135
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.
Akslen LA; Puntervoll H; Bachmann IM; Straume O; Vuhahula E; Kumar R; Molven A
Melanoma Res; 2008 Feb; 18(1):29-35. PubMed ID: 18227705
[TBL] [Abstract][Full Text] [Related]
9. Mutational profiling of acral melanomas in Korean populations.
Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY
Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690
[TBL] [Abstract][Full Text] [Related]
10. Analysis of KIT mutations and c-KIT expression in Chinese Uyghur and Han patients with melanoma.
Kang XJ; Shi XH; Chen WJ; Pu XM; Sun ZZ; Halifu Y; Wu XJ; Yu SR; Liu WX; Liang JQ; Luo D; Ren DY
Clin Exp Dermatol; 2016 Jan; 41(1):81-7. PubMed ID: 25917463
[TBL] [Abstract][Full Text] [Related]
11. A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimens.
Horn H; Pott C; Kalla J; Dreyling M; Rosenwald A; Ott G; Schwab M; Schaeffeler E
Pharmacogenet Genomics; 2010 Oct; 20(10):598-604. PubMed ID: 20802378
[TBL] [Abstract][Full Text] [Related]
12. MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET).
Jaremko M; Justenhoven C; Abraham BK; Schroth W; Fritz P; Brod S; Vollmert C; Illig T; Brauch H
Hum Mutat; 2005 Mar; 25(3):232-8. PubMed ID: 15706592
[TBL] [Abstract][Full Text] [Related]
13. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
14. NRAS mutations in primary and metastatic melanomas of Japanese patients.
Uhara H; Ashida A; Koga H; Ogawa E; Uchiyama A; Uchiyama R; Hayashi K; Kiniwa Y; Okuyama R
Int J Clin Oncol; 2014; 19(3):544-8. PubMed ID: 23739925
[TBL] [Abstract][Full Text] [Related]
15. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
16. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
17. Characterizations of Gene Alterations in Melanoma Patients from Chinese Population.
Luo Y; Zhang Z; Liu J; Li L; Xu X; Yao X; Dai Z; Wang X; Yang S; Wu H; Bu J; Wu Y; Xiang T; Li X
Biomed Res Int; 2020; 2020():6096814. PubMed ID: 32083130
[TBL] [Abstract][Full Text] [Related]
18. Results of first proficiency test for KRAS testing with formalin-fixed, paraffin-embedded cell lines in China.
Zhang R; Han Y; Huang J; Ma L; Li Y; Li J
Clin Chem Lab Med; 2014 Dec; 52(12):1851-7. PubMed ID: 24945428
[TBL] [Abstract][Full Text] [Related]
19. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19.
Takahashi Y; Fukuda Y; Yoshimura J; Toyoda A; Kurppa K; Moritoyo H; Belzil VV; Dion PA; Higasa K; Doi K; Ishiura H; Mitsui J; Date H; Ahsan B; Matsukawa T; Ichikawa Y; Moritoyo T; Ikoma M; Hashimoto T; Kimura F; Murayama S; Onodera O; Nishizawa M; Yoshida M; Atsuta N; Sobue G; ; Fifita JA; Williams KL; Blair IP; Nicholson GA; Gonzalez-Perez P; Brown RH; Nomoto M; Elenius K; Rouleau GA; Fujiyama A; Morishita S; Goto J; Tsuji S
Am J Hum Genet; 2013 Nov; 93(5):900-5. PubMed ID: 24119685
[TBL] [Abstract][Full Text] [Related]
20. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
Settleman J
Cancer Cell; 2009 Oct; 16(4):278-9. PubMed ID: 19800573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
